Prospective multicenter study designed to test the feasibility of the UroMems Artificial Urinary Sphincter in women
This study is a prospective, open-label, non-randomized, multi-center, single-arm, study with subjects acting as their own control designed to test the feasibility of a new artificial urinary sphincter the UroMems eAUS (investigational name of device called UroActive) in women.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
Implantation of the device
CHU Nantes
Nantes, France
Groupe Hospitalier Pitié-Salpêtrière
Paris, France
Rate of explants and revisions at 6 months after device activation
Rate of explants and revisions
Time frame: 6 months after device activation
Rate of device activation successes
Rate of device activation successes
Time frame: 5 weeks after device implantation
Number of subjects with 50% reduction or greater in 24-hour pad weight test
Number of subjects with 50% reduction or greater in 24-hour pad weight test
Time frame: 90, 185 days and annually up to 5-years after activation
Number of subjects with 75% reduction or greater in 24-hour pad weight test
Number of subjects with 75% reduction or greater in 24-hour pad weight test
Time frame: 90, 185 days and annually up to 5-years after activation
3-day bladder diary
Bladder diary will be filled in during 3 consecutive days
Time frame: at baseline, at device activation, and 90-days, 185-days and annually up to 5-years after activation
General quality of life questionnaire
General quality of life questionnaire
Time frame: at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation
Disease specific questionnaire (level of incontinence)
Disease specific questionnaire (level of incontinence)
Time frame: at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Disease specific questionnaire (symptoms and quality of life)
Disease specific questionnaire (symptoms and quality of life)
Time frame: at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation
Disease specific questionnaire (sexual activity)
Disease specific questionnaire (sexual activity)
Time frame: at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation
Disease specific questionnaire (quality of life)
Disease specific questionnaire (quality of life)
Time frame: at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation
Disease specific questionnaire (type of incontinence)
Disease specific questionnaire (type of incontinence)
Time frame: at baseline, at device activation and 90-days, 185-days and annually up to 5-years after activation
Post void residuals
Post void residuals will be measured to assess the bladder function
Time frame: Baseline, within 45 days after baseline (device implantation), 14 days after implantation, 5 weeks after implantation (device activation), and 14, 30, 90, 185 days and annually up to 5-years after activation
Patient satisfaction
Patient satisfaction questionnaire
Time frame: 5 weeks after device implantation (device activation), and 14, 30, 90, 185 days and annually up to 5-years after activation
Physician satisfaction questionnaire
Questionnaire to assess the physician satisfaction regarding the procedure and the device
Time frame: Within 45 days after baseline (device implantation), 5 weeks after implantation (device activation), and 14, 30, 90, 185 days and annually up to 5-years after activation
Rate of adverse events
All categories: serious/not serious events and device- and procedure-related effects
Time frame: Baseline, within 45 days after baseline (device implantation), 14 days after implantation, 5 weeks after implantation (device activation), and 14, 30, 90, 185 days and annually up to 5-years after activation